在发展中国家新生儿ICU实施智能抗生素使用计划以减少不必要的抗生素使用:一项前瞻性中断时间序列研究
该研究在一个转诊中心的三级至四级新生儿ICU开展前瞻性中断时间序列研究,纳入2015至2017年住院期间接受抗生素的全部13,540名婴儿,比较实施抗生素方案(前瞻性靶向抗生素管理审计)前后的差异。主要结局为每1000患者日总抗生素治疗天数(DOT)的变化。实施后抗生素总量从基线的543 DOT/1000患者日显著降至干预期的380 DOT/1000患者日(p=0.0001),住院时间从11.4%降至6.5%(p=0.01),多重耐药菌定植率从1.4%降至1.0%(p=0.02),总体再入院率两组无差异(1.2% vs 1.1%,p=0.16)。作者认为该计划有效减少抗生素暴露且不影响医疗质量。
要点
- 在三级至四级新生儿ICU实施智能抗生素使用计划后,抗生素总使用量从543 DOT/1000患者日降至380 DOT/1000患者日(p=0.0001)。
- 干预期间住院时间从基线的11.4%降至6.5%(p=0.01),多重耐药菌定植率从1.4%降至1.0%(p=0.02)。
- 安全性结局(感染再入院、晚发型脓毒症、坏死性小肠结肠炎或死亡)在干预期与基线期无差异。
- 总体再入院率两组无差异(1.2% vs 1.1%,p=0.16)。
- 作者认为即使在发展中国家,通过针对特殊管理目标定制抗生素管理计划也是可实现的。
适用人群与场景
- 2015至2017年在一个转诊中心三级至四级新生儿ICU住院期间接受抗生素的全部13,540名婴儿。
处置流程与药物剂量
- 干预措施为前瞻性靶向抗生素管理计划审计,通过监测和评估所有抗生素使用情况来实施抗生素方案。
研究设计与关键结果
- 研究设计为前瞻性中断时间序列研究,比较实施抗生素方案前(基线)与后(干预)两个时间段,中断期为29个月。
- 主要结局为每1000患者日总抗生素治疗天数(DOT)的变化:基线543 DOT/1000患者日 vs 干预380 DOT/1000患者日(p=0.0001)。
- 住院时间从基线的11.4%降至干预期的6.5%(p=0.01)。
- 多重耐药菌定植率从1.4%降至1.0%(p=0.02)。
- 总体再入院率两组无差异(1.2% vs 1.1%,p=0.16)。
- 安全性结局(感染再入院、胎龄≤32周婴儿的晚发型脓毒症(住院时间)、坏死性小肠结肠炎或死亡)在干预期与基线期无差异。
证据类型、等级与局限
- 证据类型:前瞻性中断时间序列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,智能抗生素使用计划的实施有效减少了抗生素暴露,且未影响医疗质量。
- 作者认为,抗生素管理计划通过针对特殊管理目标进行定制,即使在发展中国家也是可实现的。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to implement our Smart Use of Antibiotics Program to ensure the proper use of antimicrobials, improve patient care and outcomes, and reduce the risks of adverse effects and antimicrobial resistance.
DESIGN: We compared the time periods before (baseline) and after (intervention) the implementation of an antibiotic protocol by performing surveillance and assessments of all antibiotic use during a 29-month interrupted period.
SETTING: Level 3-4 neonatal ICU in one referral center.
PATIENTS: All 13,540 infants who received antibiotics during their hospital stay from 2015 to 2017.
INTERVENTIONS: Prospective audit of targeted antibiotic stewardship program.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was the change in total antibiotic days of therapy per 1,000 patient-days between the baseline and intervention periods. The secondary outcomes included readmissions for infection, late-onset sepsis (length of stay), necrotizing enterocolitis, or death in infants at 32 weeks of gestation or younger and the prevalence of multidrug-resistant organism colonization. No differences in safety outcomes were observed between the intervention and baseline periods. Following the implementation of our Smart Use of Antibiotics Program, the total quantity of antibiotics in the intervention phase was significantly decreased from 543 days of therapy per 1,000 patient-days to 380 days of therapy/1,000 patient-days compared with that of baseline (p = 0.0001), which occurred in parallel with a reduction in length of stay from 11.4% during the baseline period to 6.5% during the intervention period (p = 0.01). A reduced multidrug-resistant organism rate was also observed following Smart Use of Antibiotics Program implementation (1.4% vs 1.0%; p = 0.02). The overall readmission rate did not differ between the two periods (1.2% vs 1.1%; p = 0.16).
CONCLUSIONS: Smart Use of Antibiotics Program implementation was effective in reducing antibiotic exposure without affecting quality of care. Antibiotic stewardship programs are attainable through tailoring to special stewardship targets even in a developing country.
参考来源
- Lu C, Liu Q, Yuan H, et al. Implementation of the Smart Use of Antibiotics Program to Reduce Unnecessary Antibiotic Use in a Neonatal ICU: A Prospective Interrupted Time-Series Study in a Developing Country. Crit Care Med. 2019. PMID: 30285980. doi:10.1097/CCM.0000000000003463
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。